- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
SIR: Renal Denervation Helps Control Hypertension
HealthDay News - Approach found to reduce resistant hypertension when current medications fail
HealthDay News - Renal denervation (RDN) appears to be safe and effective in reducing and controlling hypertension among individuals with uncontrolled hypertension when current medications fail, according to research presented at the annual meeting of the Society of Interventional Radiology, held from March 26 to 31 in Chicago.
Marc R. Sapoval, MD, PhD, of the Hôpital Européen Georges-Pompidou in Paris, and colleagues randomized 106 patients with uncontrolled hypertension, despite receiving at least three antihypertensive medications, to RDN or oral treatment (control).
After six months of follow-up, the investigators found that systolic pressure fell an average of 32 mm Hg and diastolic pressure fell an average of 12 mm Hg among those who underwent RDN. The investigators are currently expanding the initial cohort to a multicenter randomized controlled trial at 24 international sites. The researchers note that endovascular RDN may also have applicability in disease states such as heart failure, cardio-renal syndrome, hepato-renal syndrome, insulin resistance-metabolic syndrome, and the prevention of progression of chronic kidney disease and hypertension in end-stage renal disease.
"Renal denervation, a minimally invasive, effective treatment, appears to be safe in the short term with a low incidence of local complications. Its efficacy to lower blood pressure in patients with resistant high blood pressure will be better evaluated with the results of a subsequent trial," Sapoval said in a statement. "After six months, 39 percent of patients receiving the endovascular denervation treatment had reached the recommended blood pressure level and, overall, 50 percent of patients showed a measurable benefit of the intervention."
The study was funded by the catheter and specific generator manufacturer.
Copyright © 2011 HealthDay. All rights reserved.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
